Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biogen, Inc. (NQ: BIIB )

282.74 USD +3.66 (+1.31%)
Official Closing Price Updated: 7:53 PM EST, Feb 24, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Stories about Biogen, Inc.

< Previous 1 2
...
93 94 95 96 97 98 99 100 Next >
Notable Friday Option Activity: BIIB, COST, INTC
Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Biogen Inc (BIIB), where a total of 8,289 contracts have traded so far, representing... 
Tags Stocks
From Market News Video
BRIEF-Biogen and Abbvie receive positive opinion from the CHMP on zinbryta
* Biogen and abbvie receive positive opinion from the chmp on zinbryta(tm) (daclizumab) for treatment of multiple sclerosis 
Tags companyNews
From Reuters: Company News
BRIEF-European regulators recommends approval of Gilead's new HIV treatment
* EU Medicines Agency recommends approval of Biogen Inc and AbbVie Inc's daclizumab to treat multiple sclerosis 
Tags companyNews
From Reuters: Company News
Immuno-Oncology: New Products Provide Growth And Value
For now we think large cap biopharmas that pay dividends are the place to be for safety and modest growth until the technicals improve with small and mid-caps in the sector. 
Tags Stocks / Equities Healthcare ETF's
From Blogs - TalkMarkets
Biotech Boom May Continue Through Earnings Season
Biotech stocks have rallied, as several analysts believe low valuations are too good to pass up. Big industry names have ... 
Tags News General Trading Ideas
From Benzinga
BRIEF-Biogen appoints Michael Ehlers, executive VP of R&D
* Biogen appoints Michael Ehlers executive vice president, research and development Source text for Eikon: Further company coverage: 
Tags companyNews
From Reuters: Company News
Biogen Inc: Market Takes the Bull by the Horns Despite Sales Miss (BIIB)
 
Tags Market Insight, Financial Articles NASDAQ:BIIB
From InvestorPlace
Biotech Recovery Rally: Steady As She Goes-Biogen Rallies On Earnings
Biotech shares have beat the market and the QQQ up 2.48% over one month but are still recovering from the January free fall with lows in mid-February. 
Tags Healthcare Stocks / Equities Pharma/Biotech
From Blogs - TalkMarkets
Biogen Inc (BIIB) Gains on Quarterly Earnings
Biogen Inc (NASDAQ: BIIB) shares climbed 4.2% to $276.96. The company is expected to report its quarterly earnings at $4.47 per share on revenue of $2.75 billion. Share volume was 1.7 million, compared... 
From Baystreet.ca RSS Feed
Biogen Beats On 1Q Earnings By A Wide Margin
Biogen Inc.'s first quarter 2016 earnings were far better-than expected. The company posted earnings of $4.79 per share while our consensus called for EPS of $4.48. 
Tags Stocks / Equities Healthcare
From Blogs - TalkMarkets
Biogen Inc (BIIB): Embrace the “Drug Trade”
 
Tags NASDAQ:BIIB Trading Advice
From InvestorPlace
12 Stocks Moving In Thursday's Pre-Market Session
Gainers Silver Standard Resources Inc. (USA) (NASDAQ: SSRI) rose 6.44 percent to $8.60 in pre-market trading. Silver Standard ... 
Tags Markets Top Gainers Leisure Products
From Benzinga
UPDATE 1-Biogen profit beats on higher Tecfidera sales
April 21 (Reuters) - Biogen Inc reported a better-than-expected first-quarter profit helped by higher demand for its key multiple sclerosis (MS) drug, Tecfidera. 
Tags companyNews
From Reuters: Company News
BRIEF-Biogen Q1 adj shr $4.79
* Q1 earnings per share view $4.47 -- Thomson Reuters I/B/E/S 
Tags companyNews
From Reuters: Company News
Biogen first-quarter sales rise 6.7 percent
April 21 (Reuters) - Biogen Inc's quarterly sales rose 6.7 percent, helped by growing demand for its key oral multiple sclerosis (MS) drug, Tecfidera. 
Tags companyNews
From Reuters: Company News
This market already broke out to an all-time high — you just didn’t notice
Many traders sound angry about the stock market nearing a new record. If you’re part of this unhappy gang, here’s one possible consolation: The S&P already set a record, if you look at a more inclusive... 
Tags CLM6 SPX Markets/Exchanges
From MarketWatch
U.S. stocks set to fight for further gains; GM results, ECB meeting ahead
Stock futures looked set to fight to keep pushing at the door of 2016 highs as oil fought to hold to sharp gains the prior session, and a barrage of earnings and an ECB meeting loomed. 
Tags GM QCOM Health/Care
From MarketWatch
Earnings Scheduled For April 21, 2016
General Motors Company (NYSE: GM) is expected to report its quarterly earnings at $1.01 per share on revenue of $35.41 ... 
Tags BX KEY NUE
From Benzinga
What to Watch in the Day Ahead - Thursday, April 21
(The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at . Thomson One users... 
Tags companyNews
From Reuters: Company News
Notable Wednesday Option Activity: SBUX, BIIB, YUM
Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Starbucks Corp. (SBUX), where a total of 29,880 contracts have traded so far, representing... 
Tags Stocks
From Market News Video
U.S. activist investors finding fewer opportunities; compromise more common
By Svea Herbst-Bayliss, Lawrence Delevingne and Michael Flaherty 
Tags companyNews
From Reuters: Company News
Biogen Inc.: Bet on BIIB for Healthy Profits
 
Tags NASDAQ:BIIB Trading Advice
From InvestorPlace
BRIEF-Biogen says Tecfidera data confirm strong, sustained efficacy in newly diagnosed MS
* Tecfidera data confirm strong and sustained efficacy in newly diagnosed ms patients and real-world effectiveness Source text for Eikon: Further company coverage: (Bengaluru Newsroom +1-646-223-8780) 
Tags companyNews
From Reuters: Company News
Biogen Reports TECFIDERA Data Confirms Strong, Sustained Efficacy in Newly-Diagnosed MS Patients
Biogen (NASDAQ: BIIB) unveiled new TECFIDERA® (dimethyl fumarate) research that reinforces its strong and sustained efficacy in newly ... 
Tags BIIB Benzinga Press Releases
From Benzinga
What to Watch in the Week Ahead and on Monday, April 18
(The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at . Thomson One users... 
Tags companyNews
From Reuters: Company News
Rotating Into Health Care
There has been no more despised sector in the stock market for the past eight months than health care and biotech. However, a funny thing has happened over the last few weeks. Health care and biotech... 
Tags Pharma/Biotech Stocks / Equities Healthcare
From Blogs - TalkMarkets
Best Stock Charts - April 13, 2016
We talk about the latest market overview by reviewing different charts. 
Tags Stocks / Equities Technology Utilities
From Blogs - TalkMarkets
These 12 U.S. companies have increased sales for at least 60 straight quarters
And their stock prices reflect that remarkable track record, writes Phil van Doorn. 
Tags Financial Services BCR Commodities
From MarketWatch
Citi Surprised, Confused Amid Report Biogen May Divest Hemophilia Unit
Reuters reported on Friday that Biogen Inc (NASDAQ: BIIB) is exploring the sale of its hemophilia business. Citi’s Robyn ... 
Tags BIIB Analyst Color Citi
From Benzinga
Biotech Rally Fizzles: Needs Help from M&A
Biotech rally loses momentum but still is up for the week. 
Tags Stocks / Equities Pharma/Biotech Healthcare
From Blogs - TalkMarkets
< Previous 1 2
...
93 94 95 96 97 98 99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.